Evidence map›Paper›PMID 29500465›Full record

ReviewCell death & disease2018

The role of osteopontin in the progression of solid organ tumour.

Hailin Zhao, Qian Chen, Azeem Alam, Jiang Cui, Ka Chun Suen, Aurelie Pac Soo, Shiori Eguchi, Jianteng Gu, Daqing Ma

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 3 pooled it
25.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 3 syntheses or guidelines pooled it, 372 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Hailin ZhaoDepartment of Surgery and Cancer, Faculty of Medicine, Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Qian ChenDepartment of Surgery and Cancer, Faculty of Medicine, Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Azeem AlamDepartment of Surgery and Cancer, Faculty of Medicine, Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Jiang CuiDepartment of Surgery and Cancer, Faculty of Medicine, Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Ka Chun SuenDepartment of Surgery and Cancer, Faculty of Medicine, Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Aurelie Pac SooDepartment of Surgery and Cancer, Faculty of Medicine, Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Shiori EguchiDepartment of Surgery and Cancer, Faculty of Medicine, Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Jianteng GuDepartment of Anaesthesiology, Southwest Hospital, Third Military Medical University, Chongqing, China. jiantenggu@hotmail.com.
Daqing MaDepartment of Surgery and Cancer, Faculty of Medicine, Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK. d.ma@imperial.ac.uk.ORCID 0000-0002-0688-2097
Chelsea and Westminster Hospital · GBArmy Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteopontin (OPN) is a bone sialoprotein involved in osteoclast attachment to mineralised bone matrix, as well as being a bone matrix protein, OPN is also a versatile protein that acts on various receptors which are associated with different signalling pathways implicated in cancer. OPN mediates various biological events involving the immune system and the vascular system; the protein plays a role in processes such as immune response, cell adhesion and migration, and tumorigenesis. This review discusses the potential role of OPN in tumour cell proliferation, angiogenesis and metastasis, as well as the molecular mechanisms involved in these processes in different cancers, including brain, lung, kidney, liver, bladder, breast, oesophageal, gastric, colon, pancreatic, prostate and ovarian cancers. The understanding of OPN's role in tumour development and progression could potentially influence cancer therapy and contribute to the development of novel anti-tumour treatments.

Indexed as

Biomarkers, TumorCell AdhesionCell MovementCell ProliferationDisease ProgressionHumansMolecular Targeted TherapyNeoplasm MetastasisNeoplasmsNeovascularization, PathologicOsteopontinBiomarkers, TumorOsteopontin

Identifiers

PMID29500465
PMCPMC5834520
OpenAlexW2790339676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.